- Corporate Officers - H
- Henderson John T
Insider Trading History of Henderson John T
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Henderson John T since 1.
This trader's CIK number is 1226488.
At the time of last reporting, Henderson John T was the Director of Cytokinetics Inc. (stock ticker symbol CYTK).
Also see all insider trading activities at Cytokinetics Inc.
Note that in the past
HENDERSON JOHN T also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Cytokinetics Inc (CYTK) by Henderson John T
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2025 | CYTK | 0 | $0 | 3,190 | $123,325 | 20,000 | $124,200 |
2024 | CYTK | 0 | $0 | 22,342 | $1,579,518 | 21,872 | $131,896 |
2023 | CYTK | 0 | $0 | 2,458 | $89,323 | 13,020 | $87,494 |
2021 | CYTK | 0 | $0 | 11,836 | $418,578 | 11,836 | $78,794 |
2020 | CYTK | 6,000 | $51,426 | 3,858 | $104,425 | 7,191 | $106,193 |
2019 | CYTK | 90,000 | $771,390 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Myriad Genetics Inc (MYGN) by Henderson John T
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2019 | MYGN | 7,000 | $164,220 | 0 | $0 | 0 | $0 |
2018 | MYGN | 0 | $0 | 30,000 | $1,261,800 | 30,000 | $731,700 |
2017 | MYGN | 6,000 | $111,922 | 30,000 | $909,030 | 30,000 | $493,800 |
2016 | MYGN | 0 | $0 | 30,000 | $614,815 | 30,000 | $317,999 |
2014 | MYGN | 0 | $0 | 30,000 | $1,123,645 | 30,000 | $228,000 |
2012 | MYGN | 0 | $0 | 40,000 | $1,105,560 | 40,000 | $265,200 |
2009 | MYGN | 300 | $9,819 | 10,000 | $824,580 | 10,000 | $172,300 |
Yearly summary of insider trading at Myriad Pharmaceuticals, Inc. (MYRX) by Henderson John T
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2013 | MYRX | 0 | $0 | 0 | $0 | 32,500 | $48,100 |
Insider trading activities at 3 companies by Henderson John T:
1. Cytokinetics Inc (CYTK)
2. Myriad Genetics Inc (MYGN)
3. Myriad Pharmaceuticals, Inc. (MYRX)
Table 1. Insider trading of Cytokinetics Inc (CYTK) by Henderson John T
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2025-04-15 | CYTK | Option Ex | 20,000 | 6.21 | 124,200 |
2025-04-15 | CYTK | Sale | 3,190 | 38.66 | 123,325 |
2024-12-11 | CYTK | Option Ex | 11,872 | 7.37 | 87,496 |
2024-12-11 | CYTK | Sale | 1,780 | 50.42 | 89,747 |
2024-04-25 | CYTK | Sale | 10,562 | 64.54 | 681,671 |
2024-02-14 | CYTK | Sale | 5,000 | 76.48 | 382,400 |
2024-02-14 | CYTK | Option Ex | 5,000 | 4.44 | 22,200 |
2024-01-12 | CYTK | Option Ex | 5,000 | 4.44 | 22,200 |
2024-01-12 | CYTK | Sale | 5,000 | 85.14 | 425,700 |
2023-12-18 | CYTK | Option Ex | 13,020 | 6.72 | 87,494 |
2023-12-18 | CYTK | Sale | 2,458 | 36.34 | 89,323 |
2021-11-05 | CYTK | Option Ex | 8,503 | 5.88 | 49,997 |
2021-11-05 | CYTK | Sale | 8,503 | 40.00 | 340,120 |
2021-04-01 | CYTK | Option Ex | 3,333 | 8.64 | 28,797 |
2021-04-01 | CYTK | Sale | 3,333 | 23.54 | 78,458 |
2020-12-31 | CYTK | Sale | 858 | 20.31 | 17,425 |
2020-12-31 | CYTK | Option Ex | 858 | 12.96 | 11,119 |
2020-10-05 | CYTK | Option Ex | 3,000 | 12.96 | 38,880 |
2020-10-05 | CYTK | Sale | 3,000 | 29.00 | 87,000 |
2020-05-19 | CYTK | Option Ex | 3,333 | 16.86 | 56,194 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
2019-11-19 | CYTK | Buy | 6,000 | 8.57 | 51,426 |
Table 2. Insider trading of Myriad Genetics Inc (MYGN) by Henderson John T
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2019-11-07 | MYGN | Buy | 7,000 | 23.46 | 164,220 |
2018-07-11 | MYGN | Sale | 30,000 | 42.06 | 1,261,800 |
2018-07-11 | MYGN | Option Ex | 30,000 | 24.39 | 731,700 |
2017-09-01 | MYGN | Option Ex | 30,000 | 16.46 | 493,800 |
2017-09-01 | MYGN | Sale | 30,000 | 30.30 | 909,030 |
2017-02-23 | MYGN | Buy | 4,000 | 18.58 | 74,308 |
2017-02-22 | MYGN | Buy | 2,000 | 18.81 | 37,614 |
2016-09-12 | MYGN | Sale | 2,007 | 20.21 | 40,567 |
2016-09-12 | MYGN | Option Ex | 2,007 | 10.60 | 21,274 |
2016-09-09 | MYGN | Option Ex | 27,993 | 10.60 | 296,725 |
2016-09-09 | MYGN | Sale | 27,993 | 20.51 | 574,248 |
2014-06-05 | MYGN | Option Ex | 5,000 | 7.60 | 38,000 |
2014-06-05 | MYGN | Sale | 5,000 | 35.70 | 178,510 |
2014-03-07 | MYGN | Option Ex | 20,000 | 7.60 | 152,000 |
2014-03-07 | MYGN | Sale | 20,000 | 37.86 | 757,200 |
2014-03-05 | MYGN | Sale | 5,000 | 37.59 | 187,935 |
2014-03-05 | MYGN | Option Ex | 5,000 | 7.60 | 38,000 |
2012-12-10 | MYGN | Sale | 40,000 | 27.64 | 1,105,560 |
2012-12-10 | MYGN | Option Ex | 40,000 | 6.63 | 265,200 |
2009-05-13 | MYGN | Buy | 300 | 32.73 | 9,819 |
2009-02-05 | MYGN | Option Ex | 10,000 | 17.23 | 172,300 |
2009-02-05 | MYGN | Sale | 10,000 | 82.46 | 824,580 |
Table 3. Insider trading of Myriad Pharmaceuticals, Inc. (MYRX) by Henderson John T
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2013-01-18 | MYRX | Option Ex | 32,500 | 1.48 | 48,100 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Henderson John T
(Director of Cytokinetics Inc at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.